KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
300497 Jiangxi Fushine Pharmaceutical
- 9.84
- -0.19-1.89%
Market Closed Dec 13 15:00 CST
5.41BMarket Cap-29.82P/E (TTM)
10.05High9.82Low105.62KlotVolume10.03Open10.03Pre Close104.36MTurnover2.34%Turnover RatioLossP/E (Static)550.00MShares13.6852wk High2.26P/B4.44BFloat Cap5.6252wk Low12.04Limit Up451.62MShs Float29.40Historical High8.02Limit Down2.29%Amplitude2.55Historical Low--Dividend TTM9.88Avg Price63.52KlotAsk--Div YieldTTM100Lot Size41.11KlotBid
Jiangxi Fushine Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -14.66%694.55M | 32.39%474.87M | 62.64%202.52M | 13.95%1.2B | 7.22%813.87M | -26.83%358.69M | -49.40%124.52M | 16.40%1.05B | -1.71%759.05M | -7.21%490.22M |
| Refunds of taxes and levies | 166.72%115.33M | 242.65%97.12M | 523.61%86.91M | -52.12%53.71M | -47.34%43.24M | -55.34%28.34M | -25.72%13.94M | 54.17%112.18M | 42.23%82.11M | 62.03%63.46M |
| Cash received relating to other operating activities | 188.27%54.48M | 282.26%46.1M | 84.24%15.54M | -61.48%20.74M | -60.11%18.9M | -69.31%12.06M | -57.57%8.44M | 11.98%53.85M | 16.30%47.38M | 21.64%39.3M |
| Cash inflows from operating activities | -1.33%864.37M | 54.87%618.09M | 107.62%304.98M | 4.54%1.27B | -1.41%876.01M | -32.70%399.09M | -48.41%146.89M | 18.87%1.22B | 2.04%888.53M | -1.14%592.98M |
| Goods services cash paid | -22.00%475.39M | 25.87%370.92M | 1.45%152.43M | 2.17%961.59M | 5.19%609.44M | -26.65%294.68M | -39.10%150.26M | 60.08%941.17M | 21.02%579.37M | 30.71%401.77M |
| Staff behalf paid | -11.64%143.63M | -11.70%98.65M | -12.90%51.52M | -8.71%212.35M | -7.41%162.55M | -5.72%111.72M | 5.87%59.15M | 38.49%232.6M | 39.06%175.57M | 32.18%118.5M |
| All taxes paid | -17.37%23.52M | -1.01%19.16M | 51.07%11.66M | -34.89%37.87M | -39.31%28.46M | -39.18%19.36M | -2.89%7.72M | -36.85%58.16M | -48.32%46.89M | -53.50%31.83M |
| Cash paid relating to other operating activities | -22.43%71.46M | -25.09%42.64M | -31.99%16.72M | 17.96%127.57M | 11.26%92.13M | 10.98%56.92M | 6.21%24.59M | 2.67%108.14M | 22.61%82.8M | 16.57%51.29M |
| Cash outflows from operating activities | -20.01%714.01M | 10.09%531.37M | -3.88%232.34M | -0.05%1.34B | 0.90%892.58M | -20.00%482.68M | -27.56%241.72M | 40.57%1.34B | 15.90%884.63M | 18.44%603.39M |
| Net cash flows from operating activities | 1,007.39%150.36M | 203.74%86.72M | 176.59%72.64M | 46.41%-64.76M | -524.67%-16.57M | -703.24%-83.59M | -93.69%-94.83M | -267.10%-120.85M | -96.37%3.9M | -111.52%-10.41M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | ---- | --0 | ---- | -81.15%46.98M | -81.12%47.09M | -80.60%48.48M | 8,031.08%50.37M | -44.33%249.2M | -19.31%249.36M | 25.38%249.86M |
| Cash received from returns on investments | 14.22%890.29K | 16.39%846.5K | 49.18%51.61K | -3.95%831.66K | -9.98%779.48K | -16.00%727.31K | --34.59K | 0.00%865.89K | -21.31%865.89K | -4.31%865.89K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 1.83%856.9K | 1,143.39%835.21K | -62.74%3.11K | -57.71%1.61M | 4.55%841.47K | -81.06%67.17K | -90.58%8.34K | 1,185.02%3.81M | 140.41%804.88K | 16.18%354.69K |
| Cash inflows from investing activities | -96.41%1.75M | -96.59%1.68M | -99.89%54.72K | -80.53%49.42M | -80.60%48.71M | -80.38%49.27M | 312.49%50.42M | -45.40%253.88M | -19.14%251.03M | 25.24%251.08M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -42.88%127.03M | -45.81%87.29M | -59.97%41.38M | -47.27%242.23M | -42.80%222.4M | -43.07%161.09M | -44.35%103.37M | -32.40%459.41M | -15.60%388.83M | 7.48%282.98M |
| Cash paid to acquire investments | -96.10%6.3M | --0 | ---- | -46.60%161.7M | -46.60%161.7M | -29.51%161.7M | 351.68%161.7M | -41.87%302.8M | -4.13%302.8M | -13.64%229.4M |
| Cash paid relating to other investing activities | ---- | ---- | ---- | ---- | --11.75M | ---- | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | -66.32%133.33M | -72.96%87.29M | -84.39%41.38M | -47.01%403.93M | -42.77%395.84M | -37.00%322.79M | 19.65%265.07M | -36.51%762.21M | -10.93%691.63M | -3.13%512.38M |
| Net cash flows from investing activities | 62.10%-131.58M | 68.70%-85.61M | 80.75%-41.32M | 30.26%-354.5M | 21.21%-347.14M | -4.68%-273.52M | -2.55%-214.65M | 30.88%-508.34M | 5.47%-440.61M | 20.44%-261.3M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | --3.5M | --3.5M | --3.5M | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Including: Cash received from capital contributions by minority shareholders of subsidiaries | --3.5M | --3.5M | --3.5M | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash from borrowing | -36.67%542M | -40.84%452M | -38.66%312M | -24.58%936.02M | -24.99%855.9M | -29.32%764M | -16.07%508.62M | 18.46%1.24B | 45.05%1.14B | 175.77%1.08B |
| Cash received relating to other financing activities | ---- | ---- | --95.76K | --20.42M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash inflows from financing activities | -36.27%545.5M | -40.38%455.5M | -37.95%315.6M | -22.93%956.44M | -24.99%855.9M | -29.32%764M | -16.19%508.62M | 14.65%1.24B | 38.91%1.14B | 153.28%1.08B |
| Borrowing repayment | -21.36%515.89M | -17.91%424.39M | -12.56%358.5M | -12.10%729.98M | -8.20%655.98M | -22.96%516.98M | 78.26%410M | 70.01%830.49M | 100.15%714.55M | 195.62%671.05M |
| Dividend interest payment | -3.73%42.86M | -4.40%26.7M | -11.15%14.29M | 2.21%55.79M | 2.39%44.53M | 4.45%27.93M | 26.59%16.08M | -60.78%54.58M | -66.27%43.49M | 131.58%26.74M |
| Cash payments relating to other financing activities | ---- | -99.36%707.55K | --377.36K | -71.33%20.91M | ---- | 57.40%110M | ---- | -30.60%72.94M | 89.37%69.75M | 3,953.37%69.89M |
| Cash outflows from financing activities | -20.24%558.75M | -31.01%451.79M | -12.42%373.17M | -15.80%806.68M | -15.38%700.5M | -14.69%654.9M | 35.47%426.08M | 30.73%958.01M | 58.35%827.79M | 219.51%767.67M |
| Net cash flows from financing activities | -108.53%-13.25M | -96.60%3.71M | -169.75%-57.57M | -47.08%149.76M | -50.39%155.4M | -65.18%109.1M | -71.77%82.54M | -19.06%282.99M | 4.87%313.21M | 67.98%313.33M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | 45.01%3.56M | 302.43%3.83M | 249.57%1.49M | -68.43%3M | -72.59%2.46M | -86.95%951.98K | -272.31%-993.8K | 1,189.79%9.51M | 330.89%8.96M | 1,910.52%7.3M |
| Net increase in cash and cash equivalents | 104.41%9.08M | 103.50%8.64M | 89.13%-24.77M | 20.85%-266.5M | -79.74%-205.86M | -605.11%-247.06M | -758.04%-227.94M | -7.63%-336.69M | -97.81%-114.53M | 195.51%48.91M |
| Add:Begin period cash and cash equivalents | -31.45%580.76M | -31.45%580.76M | -31.45%580.76M | -28.44%847.25M | -28.44%847.25M | -28.44%847.25M | -28.44%847.25M | -20.90%1.18B | -20.90%1.18B | -20.90%1.18B |
| End period cash equivalent | -8.04%589.84M | -1.80%589.4M | -10.23%555.98M | -31.45%580.76M | -40.02%641.4M | -51.32%600.19M | -49.18%619.31M | -28.44%847.25M | -25.68%1.07B | -14.71%1.23B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.